Contract pharmacy laws
23 laws in 22 states. A law of this kind limits what a drug maker may do to hold back 340B drugs from a pharmacy that works under contract with a covered entity, or to put conditions on sending them.
- Arkansas340B Drug Pricing Nondiscrimination Act2021Insurers, pharmacy benefit managers and other payers may not pay a pharmacy less, add separate terms or claim modifiers, or leave it out of a network on the ground that it takes part in 340B. Drug manufacturers may not deny drugs to a pharmacy that contracts with a 340B entity.
- ColoradoColorado 340B Contract Pharmacy Protection Act2025Manufacturers, their logistics providers and repackagers may not deny, restrict or limit 340B drugs reaching a covered entity, its contract pharmacy or another authorized location, and may not require claims or other data as a condition. Hospital covered entities report their 340B savings, costs and charity care each year, and may not spend savings on a listed set of items such as lobbying, advertising and board travel.
- HawaiiHRS chapter 481N2025A manufacturer may not deny, restrict or prohibit delivery of 340B drugs to a pharmacy under contract with a covered entity; it may ask for claims data, up to three years back, to check for diversion and duplicate discounts. From July 1, 2026 each covered entity reports contract pharmacy figures to the hospital trade association, which posts a combined public report from October 1, 2027.
- IllinoisPatient Access to Pharmacy Protection Act2026No person, a drug manufacturer included, may deny, restrict or place conditions on 340B drugs reaching a covered entity or its contract pharmacy, limit the number or place of contract pharmacies, or demand pricing or claims data. Covered entities file a yearly 340B report with the General Assembly and keep a policy against duplicate discounts; the state Medicaid agency reports once on 340B units and savings.
- LouisianaDefending Affordable Prescription Drug Costs Act2023Insurers, pharmacy benefit managers and other payers may not pay a 340B entity less for 340B drugs, set different terms or fees, require a 340B marker on a claim or keep it out of a network. A manufacturer or distributor may not deny, restrict or interfere with a 340B drug reaching a pharmacy under contract with a 340B entity.
- Maine24-A M.R.S. 7753 and 77542025A manufacturer may not deny, restrict or interfere with a 340B drug reaching a 340B contract pharmacy, and may not require a 340B entity to send claims or utilization data. Insurers, pharmacy benefits managers and other payers may not pay a 340B entity less for 340B drugs, set different terms or fees, require a 340B marker on a claim or keep it out of a network.
- MarylandMd. Code, Health Occupations 12-6C-09.1; Commercial Law 13-3012024A 340B manufacturer may not deny, restrict or otherwise limit a 340B drug reaching a pharmacy under contract with, or authorized by, a covered entity. The Prescription Drug Affordability Board studies the 340B program in Maryland and reports by July 1, 2026.
- MinnesotaMinn. Stat. 62J.962024A manufacturer may not restrict, prohibit or otherwise interfere with the delivery of a covered outpatient drug to a pharmacy under contract with a 340B covered entity.
- MississippiDefending Affordable Prescription Drug Costs Act2024Insurers, pharmacy benefit managers and other payers may not pay a 340B entity less for 340B drugs, set terms, fees or claim modifiers that others do not face, or keep it out of a network. A manufacturer or distributor may not deny, restrict or interfere with a 340B drug reaching a pharmacy under contract with a 340B entity.
- MissouriRSMo 376.4142024A drug manufacturer or third-party logistics provider, or an agent or affiliate of either, may not deny, restrict or prohibit a 340B drug reaching a pharmacy under contract with, or authorized by, a covered entity.
- Nebraska340B Contract Pharmacy Protection Act2025A manufacturer, its agent or affiliate, or a third-party logistics provider may not deny, restrict or prohibit a 340B drug reaching any location a 340B entity authorizes, and may not require claim, utilization or other data as a condition.
- New MexicoHB 782025A manufacturer, its agent or an affiliate may not deny, restrict or interfere with a 340B drug reaching a pharmacy under contract with a federally qualified health center or look-alike, and may not require claims or utilization data as a condition.
- North DakotaN.D.C.C. 43-15.3-082025A manufacturer, its agent or affiliate, or a third-party logistics provider may not deny or interfere with a contract pharmacy getting or dispensing 340B drugs for a covered entity, require claims or utilization data as a condition, or offer a rebate in place of a discount at the time of sale.
- Oklahoma340B Nondiscrimination Act2025Insurers, pharmacy benefit managers and other payers may not pay a 340B entity less for 340B drugs, set different terms or fees, require a 340B modifier on a claim or keep it out of a network. A manufacturer may not interfere with a 340B drug reaching a 340B entity or its contract pharmacy. A 340B entity contracts with any willing pharmacy within fifteen miles on terms both accept.
- OregonHB 23852025A manufacturer, or a third party acting for one, may not deny, restrict or otherwise interfere with a 340B drug reaching, or being dispensed by, a pharmacy in Oregon under contract with a covered entity, and may not require claim or utilization data as a condition.
- Rhode IslandDefending Affordable Prescription Drug Costs Act2025Insurers, pharmacy benefit managers and other payers may not pay a 340B covered entity or contract pharmacy less, add fees or conditions, limit network participation or require a 340B marker on a claim. A manufacturer may not interfere with a 340B drug reaching a contract pharmacy. By April 1 each year a covered entity reports its 340B costs, payments, vendors and claims, and how it uses the savings.
- South DakotaSDCL chapter 58-29G; 37-24-62025A manufacturer may not deny, restrict or prohibit a 340B drug reaching a location that a 340B entity or pharmacy has authorized to receive it, and may not require claim or utilization data as a condition.
- TennesseeTenn. Code Ann. 47-18-136 and 47-18-104(b)2025A manufacturer may not set extra requirements on a 340B entity, such as data demands, claim reversals or audit and credentialing rules, or deny or limit a 340B drug reaching the entity or a location under contract with it. A contractor that dispenses 340B drugs or runs an entity's program may not restrict the entity's contracts or choices.
- UtahUtah Code 31A-46-3112025A manufacturer may not stop a pharmacy and a 340B entity from contracting, deny them a drug, block a 340B drug reaching a location the entity authorizes, limit the time to restock or to claim 340B pricing, or demand claim or utilization data as a condition of supply.
- UtahUtah Code 31A-46-3112026Rewrites the section added in 2025: a manufacturer may not stop a pharmacy or 340B covered entity from contracting, limit 340B drugs reaching authorized locations, set time limits on restocking or claims, force a choice of supplier, demand claim or contract data as a condition, or interfere with pharmacy contracts.
- Vermont18 V.S.A. 4681 to 4685; 18 V.S.A. 94062025A manufacturer or its agent may not deny, restrict or interfere with a 340B drug reaching a covered entity's contract pharmacy, require claims or utilization data as a condition, or interfere with a contract pharmacy dispensing to eligible patients. Each hospital in the 340B program reports its 340B figures to the Green Mountain Care Board every January 31.
- WashingtonTitle 69 RCW (new chapter); chapter 43.71C RCW2026A manufacturer, or a third party acting for one, may not deny, restrict or prohibit a 340B drug reaching a covered entity, a contract pharmacy or an authorized location, and may not require data as a condition. Federally qualified health centers and certain hospitals report their 340B figures, the use of savings included, to the Health Care Authority by April 1 each year; manufacturers report 340B units and discounts.
- West VirginiaW. Va. Code 60A-8-6a2024A manufacturer, its agent or affiliate may not deny, restrict or prohibit a 340B drug reaching a location that a 340B entity has authorized to receive it, and may not require claims or utilization data as a condition.